amivantamab

all catalysts(11)

News(10)

• Rare EGFR mutation increases lung cancer risk 62 times in never smokers
  A rare inherited germline mutation was found to increase risk for lung cancer by 25 times, while smoking only increased risk by 4 times.
  fiercebiotech · 16d ago
• Despite 3 patient deaths, Cullinan-Taiho plan FDA filing for lung cancer pill on survival benefit
  Analysts believe Cullinan Therapeutics and Taiho Oncology can overcome the safety risks as zipalertinib “sets [a] new bar” for first-line treatment of a type of lung cancer. The candidate is alread…
  biospace · 18d ago
• Cullinan, Taiho showcase 6-month survival benefit in phase 3 trial for advanced lung cancer
  Cullinan Therapeutics and Taiho Oncology unveiled phase 3 data showing survival improvements greater than Johnson & Johnson’s Rybrevant in patients with advanced non-small cell lung cancer in the f…
  fiercebiotech · 22d ago
• New Taiho, Cullinan data heats up lung cancer drug battle
  The findings position their drug, zipalertinib, as a threat to multiple approved medicines — while setting a bar for others in testing.
  biopharma_dive · 1mo ago
• Taiho and Cullinan’s zipalertinib clears Phase 3, teeing up first-line competition
  Taiho Pharmaceutical and Cullinan Therapeutics’ cancer asset is already under FDA review in a later setting, with a decision expected by February.
  biospace · 1mo ago
• Taiho, Cullinan's lung cancer drug passes Phase 3 test, lining up Rybrevant contest
  Taiho Oncology and Cullinan Therapeutics said Wednesday that their next-gen EGFR inhibitor has cleared a registrational trial in the front-line setting of a genetically-defined type of lung cancer.…
  endpoints · 1mo ago
• Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goal
  Taiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…
  fiercebiotech · 1mo ago
• BlossomHill, Latigo outshine IPO expectations with oversubscribed debuts
  Two growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.
  fiercebiotech · 1mo ago
• BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challenger
  BlossomHill Therapeutics plans to raise $111.7 million to fund the clinical journey of its potential challenger to Tagrisso.
  fiercebiotech · 2mo ago
• Summit and Akeso sharpen case for ivonescimab with new Western data
  Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…
  biospace · 2mo ago